Allodynia News and Research RSS Feed - Allodynia News and Research

Allodynia, meaning "other pain", is a painful (noxious) response to a usually non-painful (innocuous) stimulus and can be either static or mechanical. Allodynia differs from referred pain, but can occur in areas other than the one stimulated. It is dysesthetic. Allodynia is different from hyperalgesia, an extreme reaction to a stimulus which is normally painful.
Molecular mechanisms underlying effects of acupuncture on neuropathic pain

Molecular mechanisms underlying effects of acupuncture on neuropathic pain

Peripheral or central nerve injury often leads to neuropathic pain, a chronic condition that can manifest behaviorally as spontaneous pain, hyperalgesia and allodynia, and which also results in neurological dysfunction. [More]
Winners of EFIC-Grünenthal-Grant announced

Winners of EFIC-Grünenthal-Grant announced

For the 8th time the European Federation of IASP Chapters in cooperation with the pharmaceutical company Grünenthal Group announced the EFIC-Grünenthal-Grant (E-G-G) - a grant aimed to support young scientists at an early stage of their experimental projects on clinical and human volunteer-based pain research. [More]
Nearly 1/10 stroke patients suffer from chronic and debilitating pain

Nearly 1/10 stroke patients suffer from chronic and debilitating pain

Nearly 1 in 10 stroke patients suffer chronic and debilitating pain, typically described as sharp, stabbing or burning. It's called central poststroke pain syndrome (CPSP). It was first described more than 100 years ago, and it is treatable with medications and magnetic or electrical stimulation of the brain. [More]
Scientists identify molecular mechanism central to development of osteoarthritis pain

Scientists identify molecular mechanism central to development of osteoarthritis pain

Researchers at Rush University Medical Center, in collaboration with researchers at Northwestern University, have identified a molecular mechanism central to the development of osteoarthritis (OA) pain, a finding that could have major implications for future treatment of this often-debilitating condition. [More]
Companionship can reduce nerve-related pain

Companionship can reduce nerve-related pain

Companionship has the potential to reduce pain linked to nerve damage, according to a new study. [More]
Chronic nerve pain: an interview with Professor Sally Lawson

Chronic nerve pain: an interview with Professor Sally Lawson

Chronic nerve pain results from pathological changes within a nerve that appear to be self-sustaining and thus the pain continues for a long time. [More]
Data from MAP Pharmaceuticals’ LEVADEX clinical studies to be presented at AHS meeting

Data from MAP Pharmaceuticals’ LEVADEX clinical studies to be presented at AHS meeting

MAP Pharmaceuticals, Inc. today announced that the Company will present data on LEVADEX (formerly MAP0004), an orally inhaled investigational drug for the acute treatment of migraine, at the 54th Annual Scientific Meeting of the American Headache Society (AHS) in Los Angeles, CA, June 21-24, 2012. [More]
Single fibronectin injection can prevent chronic pain development after SCI

Single fibronectin injection can prevent chronic pain development after SCI

Chronic neuropathic pain following a spinal cord injury is common and very difficult to treat, but a new therapeutic strategy requiring a one-time injection into the spinal column has potential to improve patient outcomes. [More]
Cannabidiol could prevent onset of pain associated with chemotherapy drugs

Cannabidiol could prevent onset of pain associated with chemotherapy drugs

A chemical component of the marijuana plant could prevent the onset of pain associated with drugs used in chemo therapy, particularly in breast cancer patients, according to researchers at Temple University's School of Pharmacy. [More]
Cannabidiol may help prevent paclitaxel-induced peripheral neuropathy

Cannabidiol may help prevent paclitaxel-induced peripheral neuropathy

Cannabidiol—a compound derived from marijuana—may be a promising new treatment to prevent the development of painful neuropathy in patients receiving the chemotherapy drug paclitaxel, according to animal experiments reported in the October issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society. [More]
Jefferson neurologist receives Harold G. Wolff Lecture Award for migraine headache model

Jefferson neurologist receives Harold G. Wolff Lecture Award for migraine headache model

Michael L. Oshinsky, Ph.D., assistant professor of Neurology at Jefferson Medical College of Thomas Jefferson University, and a member of the Jefferson Headache Center team, was recently named the 2011 Harold G. Wolff Lecture award recipient for creating a new animal model of migraine headache. [More]
Diabetes drug rosiglitazone can reduce development of neuropathic pain

Diabetes drug rosiglitazone can reduce development of neuropathic pain

The diabetes drug rosiglitazone (Avandia) can control inflammation leading to nerve damage and abnormal pain responses, suggests a paper in the August issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society. [More]

FDA clears Nuvo's IND for Lidocaine Spray formulation

Nuvo Research Inc., a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application filed May 27, 2011 for a novel topical Lidocaine Spray formulation (NRI-ANA), allowing for initiation of Phase 1 studies. [More]
DARA's KRN5500 reduces allodynia in Phase 2a study for neuropathic pain in cancer patients

DARA's KRN5500 reduces allodynia in Phase 2a study for neuropathic pain in cancer patients

DARA BioSciences, Inc. announced today additional positive results from its successfully completed KRN5500 Phase 2a Clinical Study for treatment of neuropathic pain in patients with cancer. Statistically significant primary endpoint results were released earlier. [More]
MAP Pharmaceuticals to present FREEDOM-301 Phase 3 trial data for migraine at EHMTIC Congress

MAP Pharmaceuticals to present FREEDOM-301 Phase 3 trial data for migraine at EHMTIC Congress

MAP Pharmaceuticals, Inc. today announced new data from the FREEDOM-301 Phase 3 trial of its investigational LEVADEX orally inhaled migraine therapy showing low recurrence rates with LEVADEX. Eight additional analyses from the LEVADEX program also will be presented during the 2010 European Headache and Migraine Trust International Congress (EHMTIC) in Nice, France. [More]
MAP Pharmaceuticals to present nine analyses on LEVADEX for migraine therapy at 2010 EHMTIC congress

MAP Pharmaceuticals to present nine analyses on LEVADEX for migraine therapy at 2010 EHMTIC congress

MAP Pharmaceuticals, Inc. today announced that the Company will present nine analyses relating to its LEVADEX™ orally inhaled migraine therapy product candidate, including analysis from the FREEDOM-301 Phase 3 trial, at the 2010 European Headache and Migraine Trust International Congress (EHMTIC) in Nice, France. [More]
MAP Pharmaceuticals reports net loss of $12.5M for second-quarter 2010

MAP Pharmaceuticals reports net loss of $12.5M for second-quarter 2010

MAP Pharmaceuticals, Inc. today announced financial results for the second quarter ended June 30, 2010. [More]

MAP Pharmaceuticals reports results from LEVADEX PK and safety clinical trial in smokers, non-smokers

MAP Pharmaceuticals, Inc. today announced results from a clinical trial comparing the pharmacokinetics (PK) and safety of LEVADEX™ orally inhaled migraine therapy with intravenous dihydroergotamine mesylate (DHE) in smokers and non-smokers. The trial was designed to measure whether systemic absorption and exposure in smokers is greater than in non-smokers. In the trial, the systemic absorption of LEVADEX was not higher and systemic exposure to DHE was not greater in smokers than in non-smokers. [More]
Laboratory mouse study shows cold sensing neural circuits develop well after birth

Laboratory mouse study shows cold sensing neural circuits develop well after birth

Cold sensing neural circuits in newborn mice take around two weeks to become fully active, according to a new study. The finding adds to understanding of the cold sensing protein TRPM8 (pronounced trip-em-ate), first identified in a Nature paper in 2002 by David McKemy of the University of Southern California. [More]
MAP Pharmaceuticals to present additional data from FREEDOM-301 Phase 3 trial of LEVADEX at AAN meeting

MAP Pharmaceuticals to present additional data from FREEDOM-301 Phase 3 trial of LEVADEX at AAN meeting

MAP Pharmaceuticals, Inc. today announced the Company will present additional post-hoc analyses from the FREEDOM-301 Phase 3 trial of its investigational LEVADEX™ orally inhaled migraine therapy in two patient subpopulations that are often difficult to treat with current triptan migraine therapies: menstrual migraine and migraine with allodynia. [More]